KRAS Mutation Detection

Methodology: 
Next-generation sequencing
Performed: 
Monday - Friday
Reported: 
10 - 14 days
Use: 

This assay is designed to detect mutations in the coding sequence of the KRAS gene. Mutations in this gene are linked to resistance to cancer therapies that target to the KRAS pathway in colorectal and other cancers.

Specimen Requirements: 

Paraffin-embedded, formalin-fixed tissue block

In case the blocks are not available, 5 unstained slides are acceptable. Ship specimens at 20° - 25° C. Tissues not fixed in formalin are unacceptable.

Unacceptable Conditions:
  • Frozen specimens
  • Specimens in formalin substitute
Stability (collection to initiation of testing):
  • Ambient: Indefinitely
Reference Values: 

No mutation present (normal)

Analytical sensitivity: 5% tumor

Interpretation Data: 

Diagnosis

Interpretation Text

Mutation Detected

Pathogenic mutations detected in the KRAS coding sequence will be reported.

No Mutation Detected

No KRAS mutation was identified in the provided specimen of this patient.

QNS

Due to inadequate specimen or less than 10% tumor cells presents in the tissue
CPT Code (s): 
  • 81275
  • 81276

Notes: 

UFHPL Test Number: 10120

Test Directory